Signs Of Change? Lilly, Merck, Janssen Report Slowing List Price Growth In 2018
Annual transparency reports from the three firms show US price increases continued, though less aggressively, and net prices declined for Lilly and Janssen.
You may also be interested in...
Lilly will launch an authorized generic version of Humalog at a 50% discount to the brand to assist patients without insurance or a high deductible, who don't benefit from rebates.
Industry's top leaders weren't exactly eager to testify on Capitol Hill. Now they might be wondering why they waited so long. Seven pharma leaders avoided missteps during a Senate Finance Committee hearing on drug pricing Feb. 26.
Letters to Lilly, Novo Nordisk and Sanofi signal potential next avenue for Finance Committee's investigation after CEO hearing on Tuesday.